智翔金泰 (688443)
Chongqing Genrix Biopharmaceutical Co., Ltd.
K-Line Chart
No K-line data available
Company NameChongqing Zhixiang Jintai Biopharmaceutical Co., Ltd.
Listing Date2023-06-20
Issue Price37.88RMB
Registered Capital3666810k RMB
Legal RepresentativeLiu Zhigang
Registered AddressArea A, Building 2, No. 699 Malu Avenue, Banan District, Chongqing
IndustryBiological Products
Main BusinessResearch, development, production, and sales of antibody drugs.
Company ProfileChongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. is an innovation-driven biopharmaceutical company. Its main business is the research, development, production, and sales of antibody drugs. Its pipeline products include monoclonal antibody drugs and bispecific antibody drugs. The company has established five technology platforms for source innovation, including a monoclonal antibody drug discovery platform based on a novel phage display system and a bispecific antibody drug discovery platform. In the drug development phase, the company has established an efficient recombinant antibody drug process development platform. Based on these platforms, the company has initiated the development of several monoclonal antibody drugs and bispecific antibody drugs. Among them, GR1501 is the first anti-IL-17 monoclonal antibody from a domestic company to enter Phase III clinical trials, GR1603 is the first anti-IFNAR1 monoclonal antibody from a domestic company to enter Phase I clinical trials, and GR1801 is the first anti-rabies virus G protein bispecific antibody in China to enter clinical trials.
The company integrates advantages in capital, talent, and technology, improving the full-chain platform from molecular discovery, process development and quality research, clinical research to industrial implementation. It accelerates the construction of its industrial base, committed to continuously providing patients with reliable and affordable biotech drugs to meet unmet clinical needs.
Stock Details
1. Key Indicators
- Total Shares(W): 36668.00
- Circulating A-Shares(W): 11668.00
- Earnings Per Share(RMB): -0.9100
- Net Assets Per Share(RMB): 4.8757
- Operating Revenue(W RMB): 20755.53
- Total Profit(W RMB): -33259.25
- **Net Profit Attributable to Parent(W RMB) **: -33259.25
- Net Profit Growth Rate(%): 39.12
- Weighted Return on Equity(%): -17.0100
- Operating Cash Flow Per Share(RMB): -0.7120
- Undistributed Profit Per Share(RMB): -7.5008
- Capital Reserve Per Share(RMB): 11.4319
2. Main Business
The main business covers:
- Research, development, production, and sales of antibody drugs
3. Company Basic Information
- Company Name: Chongqing Zhixiang Jintai Biological Pharmaceutical Co., Ltd.
- Listing Date: 2023-06-20
- Industry: Pharmaceutical Manufacturing
- Address: Area A, Building 2, No. 699 Malu Avenue, Banan District, Chongqing
- Website: https://www.genrixbio.com/
- Company Profile: On November 26, 2021, ShineWing Certified Public Accountants (Special General Partnership) issued the audit report XYZH/2021BJAA110953. As of September 30, 2021, the net assets of Zhixiang Limited were 391.9364 million RMB. On November 26, 2021, Beijing Zhongtonghua Asset Appraisal Co., Ltd. issued the asset appraisal report Zhongtonghua Ping Bao Zi (2021) No. 011777. As of the appraisal base date September 30, 2021, the book value of Zhixiang Limited's net assets was 391.9364 million RMB, and the appraisal result of net assets was 476.5390 million RMB. On December 13, 2021, Zhixiang Limited held a shareholders' meeting and passed a resolution agreeing to convert Zhixiang Limited entirely into a joint stock limited company with all shareholders of Zhixiang Limited as the promoters. All promoters converted the audited net assets of Zhixiang Limited, 391.9364 million RMB, into 275 million shares at a ratio of 1:0.7016444. The original shareholders of Zhixiang Limited subscribed for shares with the net assets corresponding to their respective shareholding ratios in Zhixiang Limited. On December 13, 2021, all shareholders of Zhixiang Limited signed the "Sponsor Agreement for Chongqing Zhixiang Jintai Biological Pharmaceutical Co., Ltd. (Preparation)" and unanimously agreed to convert Zhixiang Limited entirely into a joint stock limited company. On December 14, 2021, the company held its founding meeting and the first interim shareholders' meeting of 2021, reviewing and passing relevant proposals including the "Proposal on the Establishment of Chongqing Zhixiang Jintai Biological Pharmaceutical Co., Ltd.", agreeing to convert Zhixiang Limited entirely into a joint stock limited company. On January 11, 2022, ShineWing Certified Public Accountants (Special General Partnership) issued the capital verification report XYZH/2022BJAA110065, verifying that as of December 17, 2021, the company had received the registered capital of 275 million RMB paid by all promoters. On December 17, 2021, the Chongqing Market Supervision Administration issued the "Business License" to the company. Unified Social Credit Code: 91500113MA5U36LJ53.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | ICBC Credit Suisse Frontier Healthcare Equity Securities Investment Fund Class A | Fund | 408.65 | 3.50 |
| 2 | Shanghai Xinxi Investment Management Co., Ltd. - Shenzhen Xinxi Fuxing Investment Partnership (Limited Partnership) | Corporate | 333.33 | 2.86 |
| 3 | Shenzhen Oriental Fortune Sea Venture Capital Management Co., Ltd. - Shenzhen Fuhai Junyong No. 4 Venture Capital Enterprise (Limited Partnership) | Corporate | 320.84 | 2.75 |
| 4 | Fullgoal Enhanced Bond Securities Investment Fund Class A | Fund | 300.00 | 2.57 |
| 5 | Haitong Innovation Securities Investment Co., Ltd. | Securities Firm | 292.15 | 2.50 |
| 6 | Penghua Pharmaceutical Technology Equity Securities Investment Fund Class A | Fund | 283.29 | 2.43 |
| 7 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 196.00 | 1.68 |
| 8 | Orient Securities (Hong Kong) Medical Upgrade Equity Initiated Securities Investment Fund Class A | Fund | 169.24 | 1.45 |
| 9 | Beijing Langzi Hana Asset Management Co., Ltd. - Chengdu Gaotou Langhan Health Industry Partnership (Limited Partnership) | Asset Management Plan | 137.50 | 1.18 |
| 10 | China Southern China Securities 1000 Exchange Traded Open-End Index Securities Investment Fund | Fund | 133.90 | 1.15 |
5. Concept Sectors
- Innovative Drugs
- Margin Trading & Securities Lending
- Loss-Making Stocks
- Heavily Held by Securities Firms
- Consecutive Losses
- Below IPO Price
- Fund Reduction
- STAR Market Growth Layer
- STAR Market Biotech
- STAR Market Growth
- STAR 100
- SSE 580
Remarks
- Data update date: 2025-11-01
- Data source: Public Market Information